Andre the Giant, Acromegaly, and Growth Hormone: What a Celebrity Pays vs. A Regular Patient

Who Was Andre the Giant and What Did He Actually Have?

Andre Rene Roussimoff, known professionally as Andre the Giant, stood 7 feet 4 inches tall and weighed over 500 pounds at his peak. He was not simply large by genetics. The clinical consensus among endocrinologists who have reviewed his documented history is that he had acromegaly, the syndrome produced when a pituitary adenoma secretes excess growth hormone (GH) after the growth plates have fused in adulthood.

The Pituitary Adenoma Behind His Size

Acromegaly affects roughly 3 to 4 people per million per year and has a prevalence of approximately 60 cases per million, according to data published in the Journal of Clinical Endocrinology and Metabolism. The condition goes undiagnosed for an average of 10 years after symptom onset because the physical changes are gradual. Andre's hands, jaw, brow ridges, and feet showed the classic acral overgrowth pattern that endocrinologists use as early clinical clues.

Why He Never Sought Treatment

Andre was born in 1946 in Coulommiers, France, and began his wrestling career in the 1960s. His size was a professional asset, not a liability. He consistently declined to discuss any diagnosis publicly. By the time he died in January 1993 at age 46, he had developed the cardiomegaly and congestive heart failure that are well-documented sequelae of long-term GH excess. A 2020 review in Pituitary confirmed that cardiovascular disease is the leading cause of excess mortality in acromegaly, accounting for roughly 60% of acromegaly-related deaths.

How Acromegaly Is Diagnosed Today

The Endocrine Society's 2014 Clinical Practice Guideline on acromegaly specifies that diagnosis requires demonstration of a GH nadir >1 ng/mL during a 75 g oral glucose tolerance test (OGTT), combined with an elevated age- and sex-adjusted IGF-1 level. The guideline states: "We recommend confirming the diagnosis of acromegaly by demonstrating elevated age- and sex-adjusted serum IGF-1 concentrations and lack of GH suppression to <1 μg/L after oral glucose."

Lab Reference Ranges That Matter

Normal fasting GH in adults is <1 ng/mL. In active acromegaly, random GH levels commonly run 5 to 100 ng/mL. IGF-1 must be interpreted against age-matched norms because levels decline with age. A 40-year-old man should have an IGF-1 below approximately 303 ng/mL; values above that threshold combined with a non-suppressible GH are diagnostic.

Imaging After Biochemical Confirmation

Once the biochemistry is positive, gadolinium-enhanced MRI of the pituitary is the standard next step. Macroadenomas (diameter >10 mm) are present in about 75% of acromegaly cases at diagnosis, per data from the European Acromegaly Registry. Microadenomas (<10 mm) produce milder IGF-1 elevations and carry better surgical cure rates.

First-Line Treatment: Surgery vs. Medical Therapy

Transsphenoidal surgery is the preferred first-line treatment for most patients with a surgically accessible adenoma, per the Endocrine Society guideline. Remission is defined as a post-operative GH nadir <1 ng/mL on OGTT and normalization of IGF-1.

Surgical Cure Rates by Tumor Size

In a meta-analysis of 6,000+ patients published in the European Journal of Endocrinology, remission rates after transsphenoidal surgery were approximately 75 to 85% for microadenomas and 40 to 50% for macroadenomas. Recurrence over 10 years occurs in about 2 to 8% of those initially in remission.

When Surgery Fails or Is Not Possible

Patients with residual GH excess after surgery, or those who are poor surgical candidates, move to medical therapy. The two main drug classes are somatostatin receptor ligands (SRLs) and the GH receptor antagonist pegvisomant.

Somatostatin receptor ligands. Octreotide LAR (Sandostatin LAR, Novartis) dosed at 10 to 40 mg intramuscularly every 28 days is the most prescribed SRL globally. A phase III trial published in JCEM showed IGF-1 normalization in 54% of patients at 12 months on octreotide LAR 30 mg. Lanreotide depot (Somatuline Depot, Ipsen), dosed 60 to 120 mg subcutaneously every 28 days, produced IGF-1 normalization in 53.9% of patients in the PRIMARYS trial (N=90).

Pegvisomant. The GH receptor antagonist pegvisomant (Somavert, Pfizer), at 10 to 30 mg subcutaneously daily, normalized IGF-1 in 63 to 97% of patients across trials, per a 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism. The FDA approved pegvisomant in 2003; the current prescribing information is available on FDA.gov.

The Real Cost of Acromegaly Treatment: A Line-by-Line Breakdown

Acromegaly therapy is expensive. The numbers below are drawn from published wholesale acquisition cost (WAC) data and publicly available pharmacy benefit analyses.

Drug Costs Without Insurance

Octreotide LAR 30 mg per vial: approximately $3,200, $3,800 at WAC as of 2024. Because injections are monthly, annual drug costs run $38,000, $46,000 before any rebates. Lanreotide depot 120 mg per syringe: approximately $4,500, $5,500 WAC, yielding $54,000, $66,000 annually. Pegvisomant 30 mg daily: list price can exceed $100,000 per year, making it one of the most expensive maintenance therapies in endocrinology. A 2021 cost analysis in Pituitary found that total acromegaly-related healthcare costs in the United States averaged $61,000 per patient per year.

What an Insured Standard Patient Actually Pays

Commercial insurance plans that cover octreotide LAR typically require a prior authorization documenting elevated IGF-1, confirmed pituitary adenoma on MRI, and failure or contraindication of surgery. The process takes 2 to 6 weeks on average. After approval, specialty tier cost-sharing under a standard employer plan runs $500, $2,000 per month depending on plan design. Novartis offers a patient assistance program for Sandostatin LAR that can reduce costs to zero for patients below 400% of the federal poverty level, per the manufacturer's current program documentation.

Medicare Part B covers injectable octreotide LAR under the medical benefit (not Part D) because it is physician-administered. The 2024 Medicare allowable for octreotide LAR 30 mg (HCPCS J2353) is approximately $1,700 per injection, with a 20% coinsurance leaving the patient responsible for roughly $340 per month after the Part B deductible.

Celebrity Access and the Concierge Premium

High-profile patients and celebrities dealing with rare endocrine disorders like acromegaly can access a parallel system of care that diverges from the standard insurance pathway in several concrete ways.

How Concierge Endocrinology Works

Concierge or direct-specialty practices charge annual membership fees ranging from $5,000 to $50,000 in major metropolitan markets. That fee purchases same-week appointments, direct physician phone access, and in some cases in-office compounding or specialty pharmacy arrangements. Drug costs are not eliminated by the membership fee, but concierge practices often have established relationships with specialty pharmacies that can dispense within 48 hours rather than the 2 to 4 weeks a standard prior authorization requires.

For a drug like lanreotide depot, the cash price at a concierge-affiliated specialty pharmacy may carry a 20 to 40% markup over WAC to cover the logistics of expedited cold-chain delivery. A celebrity paying $6,000, $7,700 per injection rather than the WAC $4,500, $5,500 is essentially paying for speed and privacy, not a pharmacologically different product.

Discretion as a Paid Feature

Privacy is a concrete driver of celebrity healthcare spending. A standard endocrinology practice files claims through insurance, which generates an explanation of benefits (EOB) document that can, in some circumstances, be discoverable in litigation or appear in insurance databases. A patient paying fully out-of-pocket at a concierge practice generates no insurance record. For a public figure managing a condition that affects physical appearance and cognitive function, that discretion carries real value.

The HealthRX Celebrity vs. Standard Patient Cost Framework for acromegaly breaks the total annual treatment cost into four buckets: (1) diagnostic workup ($2,000, $8,000), (2) surgical or radiation intervention ($30,000, $80,000 one-time), (3) ongoing medical therapy ($38,000, $120,000/year), and (4) surveillance (biannual IGF-1, MRI every 1 to 3 years, colonoscopy every 5 to 10 years per Endocrine Society guidance). A celebrity paying entirely out-of-pocket in a concierge model should expect total first-year costs of $120,000, $250,000. An insured standard patient with commercial coverage and a typical specialty tier should expect $8,000, $24,000 in first-year out-of-pocket costs after the deductible.

Cardiovascular Complications: Why Treatment Timing Matters

Untreated acromegaly damages the cardiovascular system in proportion to the duration and degree of GH excess. Andre the Giant's death from heart failure at 46 is consistent with the epidemiological record.

Acromegalic Cardiomyopathy

Excess GH and IGF-1 cause left ventricular hypertrophy, diastolic dysfunction, and eventual systolic failure. A 2012 study in the European Heart Journal (N=140) found that left ventricular mass index was elevated in 62% of acromegaly patients at diagnosis. Normalization of GH and IGF-1 after treatment reduced left ventricular mass by a mean of 15% over 12 months, but the benefit was attenuated in patients who had been active for more than 10 years.

Hypertension and Arrhythmia Risk

Hypertension affects approximately 35% of acromegaly patients, per JCEM data. Ventricular arrhythmias are more common than in age-matched controls, particularly in patients with overt left ventricular hypertrophy. Standard antihypertensive therapy applies, but blood pressure control alone does not reverse the structural cardiac changes produced by GH excess. Only biochemical remission does.

Sleep Apnea: The Underappreciated Comorbidity

Soft tissue overgrowth in the pharynx and tongue causes obstructive sleep apnea (OSA) in 60 to 70% of acromegaly patients, according to a 2013 meta-analysis in Sleep Medicine Reviews. Andre the Giant reportedly slept sitting upright in later years, a posture consistent with severe untreated OSA.

CPAP therapy is appropriate while awaiting biochemical control, but surgical or medical normalization of GH/IGF-1 is needed for structural improvement. A 2014 study in JCEM found that 12 months of octreotide LAR reduced apnea-hypopnea index (AHI) by a mean of 38%, with residual OSA requiring continued CPAP in many patients.

Colon Cancer Surveillance: A Specific and Actionable Risk

Acromegaly increases colorectal cancer risk. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=17 studies) found that colon polyp prevalence was 3.0-fold higher in acromegaly patients than in controls, and colorectal cancer risk was elevated 2.5-fold. The Endocrine Society guideline recommends colonoscopy at diagnosis and every 10 years thereafter if no polyps are found, or every 5 years if polyps are present.

Andre the Giant's Case in Historical Context

Had Andre the Giant been evaluated and treated in the modern era, the treatment pathway would have started with transsphenoidal surgery. Given the likely size of his adenoma, the surgical remission probability would have been below 50%. He would then have needed octreotide LAR or lanreotide depot indefinitely, with pegvisomant added if IGF-1 remained elevated. Radiation therapy (stereotactic radiosurgery such as Gamma Knife) would have been considered if two medical agents failed to normalize IGF-1.

Endocrinologist Dr. Laurence Katznelson of Stanford University, who helped author the Endocrine Society's acromegaly guidelines, wrote that "the primary goal of therapy is normalization of GH and IGF-1, which reduces morbidity and may restore life expectancy to normal," as published in the 2014 Endocrine Society guideline document. That standard of care simply did not exist in the form we know it during Andre's active career. Octreotide received its initial FDA approval in 1988; the long-acting LAR formulation was approved in 1998, five years after his death. The prescribing history is documented in the FDA drug approval database.

Paying for Acromegaly Therapy: Practical Steps for Standard Patients

A concrete action plan matters more than a cost estimate alone.

Step 1: Confirm Biochemical Diagnosis Before Any Prescription

Insurance plans and prior authorization teams require specific lab documentation. Order a fasting IGF-1 and a 75 g OGTT with GH measured at 0, 60, and 120 minutes. Both must show abnormality before an SRL prior authorization will be approved.

Step 2: Establish Tumor Size and Surgical Eligibility

MRI with gadolinium determines whether surgery is the first step or medical therapy is primary. A fellowship-trained pituitary neurosurgeon's opinion should be part of the record submitted with the insurance authorization for medical therapy when surgery is declined or fails.

Step 3: Apply for Manufacturer Assistance Programs Before Paying List Price

Novartis (octreotide LAR), Ipsen (lanreotide depot), and Pfizer (pegvisomant) each maintain patient support programs. Income eligibility thresholds vary. Applications typically require a physician letter, income documentation, and proof of insurance denial or inadequate coverage. These programs can reduce monthly out-of-pocket costs to under $100 for qualifying patients.

Step 4: Request Bi-Annual IGF-1 and Annual Surveillance Labs

Ongoing monitoring is not optional. The Endocrine Society specifies IGF-1 and GH measurement every 3 to 6 months during dose titration, then every 6 to 12 months once stable. Skipping surveillance allows biochemical escape from control to go undetected for months.